CervoMed Inc. to Present Neflamapimod Clinical Program at 2026 Lewy Body Dementia Association Annual Meeting

CervoMed Inc. (CRVO) announced on April 7, 2026, that company representatives will present key aspects of its neflamapimod clinical program. The presentation is scheduled to take place on the same day, April 7, 2026, at the 2026 Lewy Body Dementia Association Annual Meeting in Atlanta, GA. This event provides a platform for CervoMed to disseminate information regarding its lead clinical candidate to the scientific and medical community, potentially enhancing awareness and understanding of its therapeutic pipeline. For institutional investors, this signifies ongoing development and communication regarding the company's core assets in the neurodegenerative disease space.